课题基金 / 基金详情

NSF/FDA SIR: Biomaterials for MSC Adhesion and Enrichment

NSF/FDA SIR: Biomaterials for MSC Adhesion and Enrichment
NSF/FDA SIR:用于 MSC 粘附和富集的生物材料
批准号:
1238398
负责人:
John Fisher
金额:
$12.26万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-15 至 2014-05-31

项目摘要

项目成果

John Fisher的其他基金

相似基金

相关文献

中文摘要
翻译
摘要#1238398 Fisher,John P.间充质干细胞(MSC)具有巨大的治疗潜力,因为它们能够分化成各种间充质谱系,如骨、脂肪和软骨。然而,MSC仅代表在骨髓中发现的细胞的一部分,并且缺乏独特的识别标记,证明它们难以精确分离。传统的塑料粘附有几个限制,包括骨髓中MSC和其他细胞类型之间潜在的有害相互作用,后期粘附MSC的可能损失,以及骨髓中发现的非MSC粘附细胞的不期望的扩增。这项建议有两个目的。首先通过设计一种独特的材料来克服传统塑料粘附的局限性,该材料具有调谐的机械和表面特性,以在异质群体中强烈和选择性地粘附MSC。第二,在相同的材料上培养和分化富集的捕获的MSC群体。
英文摘要
ABSTRACT #1238398Fisher, John P.Mesenchymal stem cells (MSCs) have tremendous therapeutic potential as they are capable of differentiating into various mesenchymal lineages such as bone, adipose, and cartilage. However, MSCs represent only a fraction of the cells that are found in the bone marrow and lack unique identifying markers, proving them difficult to isolate precisely. There are several limitations to traditional plasticadherence, including potentially harmful interactions between MSCs and the other cell types within the bone marrow, possible loss of late-adhering MSCs, and the undesired expansion of non-MSC adherent cells found in the bone marrow. The goal of this proposal is two-fold. First to overcome the limitations of traditional plastic adherence by designing a unique material with tuned mechanical and surface properties to strongly and selectively adhere MSCs in a heterogeneous population. Second, to culture and differentiate the enriched captured MSC population on the same material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NSF/FDA SIR: 3D Human Stem Cell Cardiac Model for Cardiac Electrophysiology Medical Device Safety Assessment
Collaborative Research: 4D Bioprinting of Near-infrared Light Responsive Smart Constructs for Pluripotent Stem Cell Derived Cardiomyocyte Engineering
NSF/FDA Scholar In Residence: 3D Cell Adhesion Assay for Cellularized Scaffold Characterization and Enhancement
Biohybrid Strategies for Decellularized Tissues
国内基金
海外基金
FDA上市药物库筛选鉴定靶向治疗ARID1A缺陷型结直肠癌的合成致死效应及分子机制研究
  • 批准号:
    82373165
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李爱民
  • 依托单位:
多维互质结构FDA雷达稀疏空时距自适应处理研究
  • 批准号:
    61771317
  • 项目类别:
    面上项目
  • 资助金额:
    62.0万元
  • 批准年份:
    2017
  • 负责人:
    阳召成
  • 依托单位:
基于FDA标记畸胎瘤细胞联合人胎盘屏障体外模型建立中药胚胎毒性评价体系的研究
  • 批准号:
    81573740
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2015
  • 负责人:
    宋殿荣
  • 依托单位: